Dr. Rashmi Kanagal-Shamanna is a practicing triple board-certified Molecular Genetic Pathologist and Hematopathologist at The University of Texas MD Anderson Cancer Center. She is a tenured Associate Professor, Co-Director of the Bone Marrow Laboratory, and the Director of the Clinical Molecular Diagnostic Laboratory (Microarray). Dr. Kanagal-Shamanna received her MD from St. John's Medical College, Bangalore, India followed by a residency in Anatomic and Clinical Pathology at Henry Ford Hospital, Detroit, Michigan. She completed her fellowships in Hematopathology, Advanced Hematopathology, and Molecular Genetic Pathology at M.D. Anderson Cancer Center. Dr. Kanagal-Shamanna's clinical responsibilities include the development and validation of genomic assays and clinical reporting, signing out bone marrow and lymph node biopsies among others. Her primary research interest is the application of novel tools for molecular profiling of hematological malignancies for prognosis and guiding therapy. Dr. Kanagal has >250 highly cited peer-reviewed publications in her field. She is the recipient of the Leukemia SPORE career development award, Ladies Leukemia League grant, and RP Foundation award. Dr. Kanagal is an invited lead author for the 2022 World Health Organization (WHO) Classification of Hematolymphoid Tumors, and author of the WHO Genetic Tumor Syndromes. Her work on myeloid neoplasms with isochromosome (17q) has led to recognizing this as a provisional entity in the latest International Consensus Classification (ICC) system. Dr. Kanagal-Shamanna is the current President of the Cancer Genomics Consortium (CGC) and co-leads the Clinical Genome (ClinGen) resource's Somatic Hematologic Malignancy Taskforce. She served as the past chair of the Professional Association Collaboration Committee tasked with the development of guidelines for the appropriate utilization of genomic assays in patient care. She serves as an editorial board member for the Cancer Genetics journal.